Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed125%
recruiting375%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717
recruitingphase_3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

NCT07217704
completedphase_2

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

NCT05641896
recruitingphase_2

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

NCT07018661

Clinical Trials (4)

Showing 4 of 4 trials
NCT07217717Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
NCT07217704Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Recruiting
NCT05641896Phase 2

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Completed
NCT07018661Phase 2

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4